Model validity for preclinical studies in precision medicine: precisely how precise do we need to be?
Open Access
- 5 April 2019
- journal article
- research article
- Published by Springer Nature in Mammalian Genome
- Vol. 30 (5-6) , 111-122
Abstract
The promise of personalized medicine is that each patient’s treatment can be optimally tailored to their disease. In turn, their disease, as well as their response to the treatment, is determined by their genetic makeup and the “environment,” which relates to their general health, medical history, personal habits, and surroundings. Developing such optimized treatment strategies is an admirable goal and success stories include examples such as switching chemotherapy agents based on a patient’s tumor genotype. However, it remains a challenge to apply precision medicine to diseases for which there is no known effective treatment. Such diseases require additional research, often using experimentally tractable models. Presumably, models that recapitulate as much of the human pathophysiology as possible will be the most predictive. Here we will discuss the considerations behind such “precision models.” What sort of precision is required and under what circumstances? How can the predictive validity of such models be improved? Ultimately, there is no perfect model, but our continually improving ability to genetically engineer a variety of systems allows the generation of more and more precise models. Furthermore, our steadily increasing awareness of risk alleles, genetic background effects, multifactorial disease processes, and gene by environment interactions also allows increasingly sophisticated models that better reproduce patients’ conditions. In those cases where the research has progressed sufficiently far, results from these models appear to often be translating to effective treatments for patients.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R24 NS098523)
- National Institutes of Health (U54 OD020351)
This publication has 86 references indexed in Scilit:
- A valid mouse model of AGRIN-associated congenital myasthenic syndromeHuman Molecular Genetics, 2011
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- A Congenital Muscular Dystrophy with Mitochondrial Structural Abnormalities Caused by Defective De Novo Phosphatidylcholine BiosynthesisThe American Journal of Human Genetics, 2011
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegenerationHuman Molecular Genetics, 2009
- Identification of an Agrin Mutation that Causes Congenital Myasthenia and Affects Synapse FunctionThe American Journal of Human Genetics, 2009
- Niemann-Pick Type C1 I1061T Mutant Encodes a Functional Protein That Is Selected for Endoplasmic Reticulum-associated Degradation Due to Protein MisfoldingJournal of Biological Chemistry, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Defective Neuromuscular Synaptogenesis in Agrin-Deficient Mutant MiceCell, 1996
- Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature, 1991